Skip to main content

Dyne Therapeutics, Inc.

corporate_fare Company Profile

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed DYN - Latest Insights

DYN
Apr 27, 2026, 4:34 PM EDT
Source: GlobeNewswire
Importance Score:
7
DYN
Apr 24, 2026, 4:46 PM EDT
Filing Type: 144
Importance Score:
7
DYN
Apr 23, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
DYN
Apr 21, 2026, 4:53 PM EDT
Filing Type: 144
Importance Score:
7
DYN
Apr 09, 2026, 4:29 PM EDT
Filing Type: PRE 14A
Importance Score:
9
DYN
Apr 01, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
DYN
Mar 11, 2026, 4:05 PM EDT
Filing Type: 144
Importance Score:
7
DYN
Mar 08, 2026, 6:00 PM EDT
Source: Reuters
Importance Score:
8
DYN
Mar 02, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
DYN
Mar 02, 2026, 7:20 AM EST
Filing Type: 10-K
Importance Score:
8
DYN
Jan 12, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
9